Department of Internal Medicine, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, South Korea.
Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
Front Endocrinol (Lausanne). 2022 Oct 31;13:1032793. doi: 10.3389/fendo.2022.1032793. eCollection 2022.
Type 2 diabetes mellitus (T2DM) is a chronic, progressive disease requiring lifelong treatment, and durable medication is essential for maintaining stable glycemic control. This study aimed to evaluate the long-term efficacy of dulaglutide in participants who have continued the drug for more than one year.
We conducted a retrospective study on 605 participants, who used dulaglutide for over one year between 2016 and 2020. Changes in glycosylated hemoglobin (HbA1c), fasting plasma glucose, and bodyweight from baseline to last prescription day were assessed. Adherence was evaluated by the proportion of days covered (PDC), and a PDC value ≥ 0.80 was considered adherent.
The mean age was 54.0 ± 11.1 years, and 46.1% were female. The mean baseline HbA1c, bodyweight, and duration of diabetes were 8.8% (72.7 mmol/mol), 75.6 kg, and 12.2 years, respectively. During the mean follow-up of 33.1 months, HbA1c and bodyweight decreased by 1.28% (14 mmol/mol, P < 0.001) and by 3.19 kg (P < 0.001), respectively. The participants were highly adherent with PDC ≥ 0.80 in 92.4% of the participants.
In T2DM patients, long-term dulaglutide treatment was effective in maintaining HbA1c and weight reduction. Dulaglutide could be a favorable option of long-term treatment in real-world clinical practice.
2 型糖尿病（T2DM）是一种慢性、进行性疾病，需要终身治疗，持久的药物治疗对于维持稳定的血糖控制至关重要。本研究旨在评估超过一年持续使用度拉鲁肽的患者的长期疗效。
我们对 2016 年至 2020 年间使用度拉鲁肽超过一年的 605 名参与者进行了回顾性研究。从基线到最后一次处方日，评估糖化血红蛋白（HbA1c）、空腹血糖和体重的变化。通过比例达标天数（PDC）评估依从性，PDC 值≥0.80 被认为是依从的。
平均年龄为 54.0±11.1 岁，46.1%为女性。平均基线 HbA1c、体重和糖尿病病程分别为 8.8%（72.7mmol/mol）、75.6kg 和 12.2 年。在平均 33.1 个月的随访期间，HbA1c 和体重分别下降了 1.28%（14mmol/mol，P＜0.001）和 3.19kg（P＜0.001）。92.4%的参与者达到了 PDC≥0.80 的高度依从性。
在 T2DM 患者中，长期度拉鲁肽治疗能有效维持 HbA1c 和减轻体重。度拉鲁肽可能是真实世界临床实践中长期治疗的一个有利选择。
